A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low ...

The approval is backed by Amgen’s (AMGN) CodeBreaK 300 trial, in which patients on sotorasib 960 mg/panitumumab recorded over three months of median survival benefit without cancer progression ...

The much-anticipated results of a trial of more than 800 participants in Japan revealed that, when coupled with standard chemotherapy, the drug panitumumab lowered the risk of death by 18% ...

These include a chemotherapy drug called panitumumab, which works by blocking EGFR in the body; the man was taking this drug as part of a chemotherapy regimen for advanced colorectal cancer.

This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments.